Latest news with #AVERSA
Yahoo
2 days ago
- Business
- Yahoo
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ('Nutriband' or the 'Company') announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors. "Our core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA fentanyl. We recently highlighted our Commercialization manufacturing process scale up with Kindeva and we are now laser focused on finalizing our development pathway to FDA approval," said Gareth Sheridan, CEO. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband Inc. Phone: 407-377-6695 Email: info@ SOURCE: Nutriband Inc.
Yahoo
30-04-2025
- Business
- Yahoo
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025. The full text of the letter is below. Dear Shareholders, Following the filing of our annual report as we wrap up a successful year packed with milestones and advances towards the commercialization of our AVERSA technology, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2024 and into 2025. Many of you have been with us from the beginning and many more joined our mission to change the pharmaceutical industry for the better by developing our Aversa technology designed to improve the safety of easily abused transdermal drugs, such as pain medications, while making them available to patients who need them. Pain patients have been struggling with inadequate care for too long, and they deserve to be able to access the medication they need. Aversa gives them this access. Today we are on track to be the world's first and only abuse deterrent technology in the transdermal space targeting abusable medications such as fentanyl and buprenorphine. Nutriband is primarily focused on working with our partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop our lead product, AVERSA™ Fentanyl, which incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch. AVERSA Fentanyl has the potential to become the world's first opioid pain patch with abuse deterrent properties and is estimated to potentially reach peak annual sales of $80M - $200M. In addition, AVERSA Buprenorphine, our next candidate for AVERSA is projected to reach peak annual sales of $70M - $130M. Nutriband recently performed an extensive evaluation of the commercial cost of goods of incorporating the Aversa technology into existing FDA-approved transdermal patches and have confirmed the viability of achieving high margins that are typically found in NDA pharmaceutical products. This past year we have made significant strides in the development and scale-up of the manufacturing process to bring the AVERSA technology closer towards commercialization. This has involved the development and refinement of our proprietary technology for commercial scale manufacturability as well as the establishment of the commercial supply chain and validation of the analytical methods required to meet FDA regulatory standards for a pharmaceutical product. The new year has already been highlighted by a significant milestone with our partner Kindeva Drug Delivery to formalize our exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. It solidifies a transition to commercial scale development for AVERSA Fentanyl. We have confidently shifted our focus from feasibility towards commercial development in support of an NDA filing and commercialization. This was a very strong show of support from our partner Kindeva which also allowed us to reduce the impact of dilution to our existing shareholders which I stress has been and will remain a core focus of the company. This was evident through our raise of $8.4M USD in April 2024 in a non-brokered private placement primarily through existing shareholders. In addition, we continued to further expand the worldwide intellectual property portfolio for our Aversa™ abuse deterrent technology, with approvals in China and its territories, Hong Kong and Macao, and a new patent recently allowed in the United States. This improves our position to bring our leading abuse deterrent platform to market and we are now patented in 46 countries around the world. While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA a global solution strategically targeting all major medical markets in the world. Our 2025 goals are ambitious yet achievable, focused on getting into the clinic to evaluate our lead product, Aversa Fentanyl, in a pivotal Human Abuse Liability (HAL) clinical trial to support an NDA filing. This involves manufacturing clinical supplies using a commercial scale process and filing an Investigational New Drug application with the FDA. We are also excited to explore new potential partnerships, internationally for our AVERSA intellectual property and will be turning our focus to potential licensing and partnership opportunities as we near closer to filing our NDA with the FDA. Financially, the team is excited by strong revenue in our Pocono Pharma subsidiary for our kinesiology tape contract manufacturing services. We strongly believe that 2025 is shaping up to be our best year on record at Pocono Pharma due to our expanding manufacturing collaboration with KT Tape, the world leader in kinesiology tape. If you haven't already taken a moment to sign up for our email alerts, be sure to do so by visiting our website: Signing up will ensure that you receive the latest news and announcements as they become available. Your continued support and belief in our vision have been pivotal to our reaching these milestones and others as we forge ahead. We remain committed to delivering innovative solutions and generating value for our shareholders. Thank you for your trust, confidence and investment in Nutriband Gareth Sheridan CEO, Nutriband Inc. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2025, filed April 28, 2025, the Forms 10-Q's filed subsequent to the Form 10-K in 2025, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband 407-377-6695Email: info@ SOURCE: Nutriband Inc. Photos accompanying this announcement are available at: in to access your portfolio
Associated Press
30-04-2025
- Business
- Associated Press
Nutriband Inc. (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Nutriband Inc. (NASDAQ:NTRB) is a pharmaceutical company with a specific focus on developing a portfolio of transdermal pharmaceutical products. The company's lead product under development is AVERSA™ Fentanyl, which is on track to becoming the first-ever abuse-deterrent transdermal fentanyl patch. AVERSA Fentanyl is currently pursuing a 505(b)(2) registration pathway, which should make it eligible for a more expedited review. For context, AVERSA is Nutriband's proprietary technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with the potential for abuse, like opioids. What makes AVERSA unique is its aversive agent coating, which leverages taste aversion to deter oral abuse and accidental exposure to transdermal opioid patch products. More than 70% of fentanyl patch abusers choose oral routes to abuse, so taste aversion addresses primary routes of abuse. That means AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. In one of the company's recent major corporate milestones, Nutriband announced that it had received notification that its patent had been granted in Macao, which protects its AVERSA abuse-deterrent transdermal technology. The technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, as well as two regions of China: Hong Kong and Macao. Interestingly, the company hasn't been structured to follow the typical biotech standard when it comes to time and cost. The company already has two revenue-generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical, along with Active Intelligence, which specializes in sports recovery products. Nutriband's revenues keep its development burn at a minimum. The company also owns its manufacturing and clinical development capabilities, which significantly reduces its costs for AVERSA and other technologies. Most notably, Nutriband partnered with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband's AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) that has a rich history in pharmaceutical innovation and manufactures millions of transdermal patches distributed worldwide. This strong partnership for AVERSA Fentanyl's commercial development has led to significant progress in the abuse-deterrent patch's development and manufacturing. Recently the two companies revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. At the same time, Nutriband revealed that it had signed an Associate Partnership agreement with Charlotte FC, which would be instrumental in helping build visibility for its brands, such as AI Tape. Management noted, 'We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.'' AVERSA's addressable market is huge, depending on how you look at it. For instance, accidental fentanyl misuse is a growing problem, as illustrated by a recent report that revealed there had been 32 cases of accidental fentanyl exposure, which occurred, resulting in 12 deaths and dozens of hospitalizations, mostly involving young children. This is where the technology comes into play, as it significantly reduces the likelihood of accidental exposure to fentanyl for children. Furthermore, AVERSA Fentanyl is well aligned with the FDA's Opioids Action Plan mission to expand access to abuse-deterrent formulations (ADFs) and to reduce the risks of misuse not just by the patient but also by other persons who obtain opioids. Upon approval of AVERSA fentanyl, the company expects that the FDA will consider requiring all fentanyl patches to be abuse deterrent, as was required for all oxycontin generics, which could potentially translate to more market share. To put the opportunity here into better context, consider this. According to Health Advances' assessment, once approved by the FDA, AVERSA Fentanyl is expected to reach peak annual sales of about $200 million. The company believes that conservative pricing will be a key component of capturing and maintaining market share in addition to real-world data and marketing. According to the Health Advances' report on AVERSA Fentanyl, Nutriband can expect to comfortably charge a 20% premium versus generics while maintaining insurance coverage and support, ideally capturing the market as the safest fentanyl patch in its class. Disclaimers: RazorPitch Inc. 'RazorPitch' is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting LLC to assist in the production and distribution of content related to MILIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: Send Email City: NAPLES State: Florida Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Nutriband Inc. (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Yahoo
04-04-2025
- Business
- Yahoo
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the 'Company')(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. 'We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.'' AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina. The Company also intends to use the relationship to promote its platform technology AVERSA and raise awareness for the technology which has the potential to be the World's first and only abuse deterrent patch platform for managing chronic pain. About Nutriband are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking StatementsCertain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. For more information, contact: Nutriband 407-377-6695Email: info@
